Loading…
Myriad Genetics is projected to rise to $6.23 by 2027, a +7% move from its current price of $5.83. MYGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $5.63 | $5.84 | $6.05 | +0.09% |
| Jul 13 | $5.55 | $5.84 | $6.15 | +0.17% |
| Jul 14 | $5.49 | $5.85 | $6.22 | +0.26% |
| Jul 15 | $5.44 | $5.85 | $6.29 | +0.35% |
| Jul 16 | $5.40 | $5.86 | $6.35 | +0.44% |
| Jul 17 | $5.36 | $5.86 | $6.40 | +0.52% |
| Jul 18 | $5.33 | $5.87 | $6.45 | +0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.33 | $5.87 | $6.45 | +0.61% |
| Week 2 | $5.16 | $5.90 | $6.75 | +1.23% |
| Week 3 | $5.03 | $5.94 | $7.01 | +1.85% |
| Week 4 | $4.94 | $5.97 | $7.23 | +2.47% |
| Week 5 | $4.85 | $6.01 | $7.44 | +3.10% |
| Week 6 | $4.79 | $6.05 | $7.64 | +3.73% |
| Week 7 | $4.73 | $6.08 | $7.83 | +4.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Myriad Genetics, Inc. is a healthcare company described as a molecular diagnostics and precision medicine company that develops molecular tests. The description notes tests for oncology, women's health, and pharmacogenomics.
Its portfolio includes MyRisk Hereditary Cancer test; BRACAnalysis CDx Germline Companion Diagnostic test; MyChoice CDx Companion Diagnostic test; Prolaris Prostate Cancer Prognostic test; EndoPredict Breast Cancer Prognostic test; Precise Tumor Molecular Profile test; Prequel Prenatal Screen; Foresight Carrier Screen; SneakPeek Early Gender DNA test; FirstGene; and GeneSight Psychotropic. It has license collaborations with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA.
The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics, Inc. (MYGN) is trading at $5.88 per share and has a market cap of $555.36M.
The stock ranks 2963 by market capitalization.
A major floor 45.6% below — a decisive break under it would weaken the trend.
The nearest floor, 31.9% below — buyers have tended to step in here.
The nearest ceiling, 4.6% above — a clean break opens room to run.
A major ceiling 27.4% above — clearing it would confirm fresh momentum.
Key MYGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MYGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.94 | Sell | $5.91 | Sell |
| MA 10 | $5.91 | Sell | $5.77 | Buy |
| MA 20 | $5.27 | Buy | $5.42 | Buy |
| MA 50 | $4.63 | Buy | $4.97 | Buy |
| MA 100 | $4.69 | Buy | $5.00 | Buy |
| MA 200 | $5.75 | Buy | $5.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.42 | Neutral |
| Stoch RSI (14) | 44.26 | Neutral |
| CCI (20) | 56.75 | Neutral |
| Williams %R (14) | -16.87 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 25.92 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 83.13 | Sell |
| TRIX (15) | 1.23 | Buy |
| Awesome (5,34) | 1.10 | Buy |
| Ultimate (7,14,28) | 63.21 | Neutral |
| Momentum (10) | 0.40 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 5.94 | Sell |
| ADX (14) | 28.76 | Buy |
| ATR (14) | 0.17 | Info |
The 30-day price range is $4.50 to $7.68.
The RSI14 is 70; the SMA50 is $4.44 and the SMA200 is $5.83. Current price sits around these moving averages. Support is at $3.55 and resistance at $5.43.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.55 | $5.83 | $8.37 | 0% | Neutral | |
| $4.81 | $6.23 | $8.61 | +7% | Neutral | |
| $5.20 | $7.00 | $10.14 | +20% | Neutral | |
| $5.48 | $7.62 | $11.45 | +31% | Bullish | |
| $6.37 | $9.11 | $14.11 | +56% | Bullish | |
| $7.47 | $10.96 | $17.43 | +88% | Bullish | |
| $7.74 | $11.63 | $18.94 | +100% | Bullish | |
| $7.98 | $12.27 | $20.41 | +111% | Bullish | |
| $7.56 | $11.89 | $20.16 | +104% | Bullish | |
| $7.57 | $12.17 | $21.01 | +109% | Bullish | |
| $10.44 | $18.52 | $34.44 | +218% | Bullish | |
| $20.86 | $44.22 | $91.53 | +658% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.55 | $5.83 | $7.10 | +0.00% |
| August 2026 | $5.23 | $6.23 | $7.66 | +6.85% |
| September 2026 | $5.25 | $6.31 | $7.87 | +1.33% |
| October 2026 | $5.10 | $6.18 | $7.80 | -2.06% |
| November 2026 | $5.18 | $6.32 | $8.05 | +2.17% |
| December 2026 | $5.30 | $6.50 | $8.37 | +2.94% |
Click any year to see its month-by-month MYGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The MYGN price prediction for 2026 points to an average of $5.83 (low $3.55, high $8.37) — a potential gain of 0% on today's $5.83. Price action looks broadly range-bound.
In 2027, MYGN is projected to trade between $4.81 and $8.61, averaging $6.23 — a potential gain of +7% from today's $5.83. That is up +7% on the projected 2026 average. A consolidation phase looks the most probable path here.
Myriad Genetics's 2028 outlook centres on $7.00, within a $5.20 to $10.14 range. That is up +12% on the projected 2027 average. That marks a +20% change versus current levels. Price action looks broadly range-bound.
By 2029, MYGN could reach as high as $11.45, with a base case around $7.62 and support toward $5.48 — roughly +31% from $5.83. Buyers look set to stay in control over this stretch.
Expect MYGN to range from $6.37 to $14.11 through 2030. The $9.11 average target implies a +56% move from current prices. That is up +20% on the projected 2029 average. Momentum favours further upside here.
The MYGN price prediction for 2031 points to an average of $10.96 (low $7.47, high $17.43) — a potential gain of +88% on today's $5.83. Buyers look set to stay in control over this stretch.
In 2032, MYGN is projected to trade between $7.74 and $18.94, averaging $11.63 — a potential gain of +100% from today's $5.83. That is up +6% on the projected 2031 average. Momentum favours further upside here.
Myriad Genetics's 2033 outlook centres on $12.27, within a $7.98 to $20.41 range. That is up +5% on the projected 2032 average. That marks a +111% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, MYGN could reach as high as $20.16, with a base case around $11.89 and support toward $7.56 — roughly +104% from $5.83. Momentum favours further upside here.
Expect MYGN to range from $7.57 to $21.01 through 2035. The $12.17 average target implies a +109% move from current prices. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The MYGN price prediction for 2040 points to an average of $18.52 (low $10.44, high $34.44) — a potential gain of +218% on today's $5.83. Momentum favours further upside here.
In 2050, MYGN is projected to trade between $20.86 and $91.53, averaging $44.22 — a potential gain of +658% from today's $5.83. That is up +139% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MYGN today (≈ 171.526587 MYGN) could be worth
$7,584.05
+$6,584.05 (+658%) by 2050 · US Dollar
Based on the average projected MYGN price of $44.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MYGNwould be worth at today's price.
$1,000 invested in MYGN on Jul 10, 2025 (≈ 181.818182 MYGN) would be worth
$1,060
+$60 (+6.0%) today · 1.06× · US Dollar
Based on a MYGN entry price of $5.5 vs. today's $5.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.99 | $973.29 | -2.7% |
| 1 month ago | $4.43 | $1,316.03 | +31.6% |
| 3 months ago | $4.35 | $1,340.23 | +34.0% |
| 6 months ago | $6.57 | $887.37 | -11.3% |
| 1 year ago | $5.5 | $1,060 | +6.0% |
| All time (5.0y) ago | $34 | $171.47 | -82.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MYGN forecast.
Our base-case forecast reaches $12.00 around 2033.
Implied market cap at $12.00: $1.13B
The multi-year forecast shows a bullish trajectory across the horizon with steadily rising averages.
In 2027 the avg is $6.14, in 2028 $7.27, and in 2029 $7.71, with 2030 the avg at $9.23 and a max of $14.76 and ROI 57%. By 2040 the avg rises to $19.66 with a max of $38.30 and ROI 234.4%, and by 2050 the avg is $46.57 with a max of $101.69 and ROI 692.1%.
This outlook continues to imply meaningful upside from today’s level, though these are estimates and not guarantees of future performance.
Tap a question to reveal the answer.
Avg $9.23 with a max of $14.76 and min $6.26; ROI 57%; sentiment BULLISH.
The forecast shows bullish sentiment with rising averages and positive ROI, e.g., 2027 avg $6.14, 2028 avg $7.27, 2029 avg $7.71, 2030 avg $9.23 with max $14.76 and ROI 57%, 2040 avg $19.66 with max $38.30 and ROI 234.4%, 2050 avg $46.57 with max $101.69 and ROI 692.1%.
No. The maximum forecast price for 2030 is $14.76.
Current price $5.88; Market cap $555.36M.
Low $4.50; High $7.68.
Myriad Genetics Community Discussion
0Share your Myriad Genetics price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.